SG10201505101VA - Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors - Google Patents
Compositions For Continuous Administration Of Dopa Decarboxylase InhibitorsInfo
- Publication number
- SG10201505101VA SG10201505101VA SG10201505101VA SG10201505101VA SG10201505101VA SG 10201505101V A SG10201505101V A SG 10201505101VA SG 10201505101V A SG10201505101V A SG 10201505101VA SG 10201505101V A SG10201505101V A SG 10201505101VA SG 10201505101V A SG10201505101V A SG 10201505101VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- continuous administration
- dopa decarboxylase
- decarboxylase inhibitors
- inhibitors
- Prior art date
Links
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
- C07C243/16—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C243/18—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17951109P | 2009-05-19 | 2009-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201505101VA true SG10201505101VA (en) | 2015-07-30 |
Family
ID=42320738
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709016RA SG10201709016RA (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
SG10201505101VA SG10201505101VA (en) | 2009-05-19 | 2010-05-17 | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
SG2011085297A SG176159A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201709016RA SG10201709016RA (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011085297A SG176159A1 (en) | 2009-05-19 | 2010-05-17 | Compositions for continuous administration of dopa decarboxylase inhibitors |
Country Status (26)
Country | Link |
---|---|
US (9) | US8193243B2 (el) |
EP (3) | EP2432454B1 (el) |
JP (3) | JP5643297B2 (el) |
KR (2) | KR101641401B1 (el) |
CN (2) | CN104546700B (el) |
AR (3) | AR078413A1 (el) |
AU (1) | AU2010250766B2 (el) |
BR (1) | BRPI1011031B8 (el) |
CA (1) | CA2761624C (el) |
CL (1) | CL2011002895A1 (el) |
CY (1) | CY1119495T1 (el) |
DK (2) | DK2432454T3 (el) |
ES (2) | ES2840748T3 (el) |
HR (2) | HRP20170805T1 (el) |
HU (2) | HUE033388T2 (el) |
IL (1) | IL216383A (el) |
LT (1) | LT2432454T (el) |
MX (2) | MX364974B (el) |
NZ (1) | NZ596963A (el) |
PL (2) | PL2432454T3 (el) |
PT (2) | PT3192500T (el) |
RU (3) | RU2559083C9 (el) |
SG (3) | SG10201709016RA (el) |
SI (1) | SI2432454T1 (el) |
WO (1) | WO2010134074A1 (el) |
ZA (1) | ZA201109037B (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN192600B (el) * | 1996-10-18 | 2004-05-08 | Hoechst Celanese Corp | |
LT2432454T (lt) | 2009-05-19 | 2017-07-10 | Neuroderm Ltd | Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui |
NZ610911A (en) * | 2010-11-15 | 2015-02-27 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
MX2014014902A (es) | 2012-06-05 | 2015-03-04 | Neuroderm Ltd | Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas. |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
CN103845318A (zh) * | 2012-12-07 | 2014-06-11 | 天津市汉康医药生物技术有限公司 | 恩他卡朋分散片 |
HRP20211442T1 (hr) * | 2013-03-13 | 2022-02-04 | Neuroderm Ltd | Kombinacija za liječenje parkinsonove bolesti |
AU2014346855B2 (en) * | 2013-11-05 | 2019-07-18 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
HRP20231716T1 (hr) * | 2014-03-13 | 2024-03-15 | Neuroderm Ltd. | Pripravci inhibitora dopa dekarboksilaze |
US10071069B2 (en) | 2014-09-04 | 2018-09-11 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof |
RU2743347C2 (ru) | 2014-10-21 | 2021-02-17 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
CN113197851A (zh) | 2015-05-06 | 2021-08-03 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
RU2018119194A (ru) | 2015-11-24 | 2019-12-25 | Нейродерм Лтд. | Фармацевтические композиции, содержащие амид леводопы, и их применения |
KR102578476B1 (ko) * | 2016-04-11 | 2023-09-13 | 유니버시티 오브 캔버라 | 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물 |
US10064834B2 (en) | 2016-05-09 | 2018-09-04 | Texas Tech University System | Carbidopa for the treatment of cancer |
EA201992685A1 (ru) * | 2017-06-05 | 2020-06-05 | Дизлин Фармасьютикалз Аб | Раствор леводопы для инфузий |
US20230123806A1 (en) * | 2017-07-07 | 2023-04-20 | Neuroderm, Ltd. | Device for subcutaneous delivery of fluid medicament |
CA3095341A1 (en) * | 2018-03-29 | 2019-10-03 | Avion Pharmaceuticals, Llc | Levodopa fractionated dose composition and use |
WO2020252257A1 (en) * | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769424A (en) * | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
US3936495A (en) * | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4642316A (en) * | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
ATE76747T1 (de) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
US5350769A (en) * | 1990-10-30 | 1994-09-27 | Ss Pharmaceutical Co., Ltd. | Antiinflammatory gel preparation |
US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
CA2143070C (en) * | 1994-02-22 | 2001-12-18 | Pankaj Modi | Oral controlled release liquid suspension pharmaceutical formulation |
GB9523833D0 (en) | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
WO1999048876A1 (en) * | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
US7201923B1 (en) * | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
ES2221385T3 (es) * | 1998-05-15 | 2004-12-16 | Warner-Lambert Company Llc | Preparaciones de gabapentina y pregabalina estabilizadas con aminoacidos y procedimiento para prepararlas. |
US6274168B1 (en) * | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US7479498B2 (en) * | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
US6348965B1 (en) * | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
GB0017387D0 (en) * | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
AU2002357137A1 (en) | 2001-12-10 | 2003-06-23 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
AU2003214551A1 (en) * | 2002-04-11 | 2003-10-20 | Ranbaxy Laboratories Limited | Controlled release pharmaceutical compositions of carbidopa and levodopa |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
EP2239260A1 (de) | 2002-10-10 | 2010-10-13 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
JP2007531701A (ja) * | 2003-07-18 | 2007-11-08 | バクスター・インターナショナル・インコーポレイテッド | 制御された相分離により調製される小球状粒子の作製方法、使用および組成物 |
US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
US7589233B2 (en) * | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
EP1670450B8 (en) * | 2003-08-29 | 2011-03-23 | Centocor Ortho Biotech Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US20050053669A1 (en) | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
CN1901880A (zh) * | 2003-10-31 | 2007-01-24 | 阿尔扎公司 | 用于增加二甲双胍吸收的组合物和剂型 |
KR20060109922A (ko) * | 2003-10-31 | 2006-10-23 | 알자 코포레이션 | 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형 |
WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
WO2006037061A2 (en) * | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2063865A1 (en) | 2006-05-31 | 2009-06-03 | Solvay Pharmaceuticals GmbH | Long term 24 hour intestinal administration of levodopa/carbidopa |
US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
JP5631734B2 (ja) * | 2007-04-06 | 2014-11-26 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 流体薬物を供給するためのシステム及び方法 |
CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
LT2432454T (lt) | 2009-05-19 | 2017-07-10 | Neuroderm Ltd | Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui |
US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
ES2673219T3 (es) | 2010-11-15 | 2018-06-20 | Neuroderm Ltd | Composición para la entrega transdérmica de agentes activos |
NZ610911A (en) | 2010-11-15 | 2015-02-27 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
WO2012079072A2 (en) | 2010-12-10 | 2012-06-14 | Synagile Corporation | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
HRP20211442T1 (hr) | 2013-03-13 | 2022-02-04 | Neuroderm Ltd | Kombinacija za liječenje parkinsonove bolesti |
HRP20231716T1 (hr) | 2014-03-13 | 2024-03-15 | Neuroderm Ltd. | Pripravci inhibitora dopa dekarboksilaze |
-
2010
- 2010-05-17 LT LTEP10725880.8T patent/LT2432454T/lt unknown
- 2010-05-17 AU AU2010250766A patent/AU2010250766B2/en active Active
- 2010-05-17 EP EP10725880.8A patent/EP2432454B1/en active Active
- 2010-05-17 SG SG10201709016RA patent/SG10201709016RA/en unknown
- 2010-05-17 NZ NZ596963A patent/NZ596963A/en not_active IP Right Cessation
- 2010-05-17 EP EP17158360.2A patent/EP3192500B1/en active Active
- 2010-05-17 RU RU2011149976/15A patent/RU2559083C9/ru active
- 2010-05-17 DK DK10725880.8T patent/DK2432454T3/en active
- 2010-05-17 KR KR1020117030315A patent/KR101641401B1/ko active IP Right Grant
- 2010-05-17 HU HUE10725880A patent/HUE033388T2/en unknown
- 2010-05-17 RU RU2015115064A patent/RU2678839C2/ru active
- 2010-05-17 MX MX2015001674A patent/MX364974B/es unknown
- 2010-05-17 ES ES17158360T patent/ES2840748T3/es active Active
- 2010-05-17 US US12/781,357 patent/US8193243B2/en active Active
- 2010-05-17 PL PL10725880T patent/PL2432454T3/pl unknown
- 2010-05-17 ES ES10725880.8T patent/ES2627655T3/es active Active
- 2010-05-17 CN CN201410800432.0A patent/CN104546700B/zh active Active
- 2010-05-17 SG SG10201505101VA patent/SG10201505101VA/en unknown
- 2010-05-17 EP EP20197759.2A patent/EP3777839A1/en active Pending
- 2010-05-17 HU HUE17158360A patent/HUE052685T2/hu unknown
- 2010-05-17 MX MX2011012315A patent/MX2011012315A/es active IP Right Grant
- 2010-05-17 PT PT171583602T patent/PT3192500T/pt unknown
- 2010-05-17 SI SI201031466T patent/SI2432454T1/sl unknown
- 2010-05-17 CA CA2761624A patent/CA2761624C/en active Active
- 2010-05-17 JP JP2012511409A patent/JP5643297B2/ja active Active
- 2010-05-17 WO PCT/IL2010/000400 patent/WO2010134074A1/en active Application Filing
- 2010-05-17 PL PL17158360T patent/PL3192500T3/pl unknown
- 2010-05-17 BR BRPI1011031A patent/BRPI1011031B8/pt active IP Right Grant
- 2010-05-17 KR KR1020167019114A patent/KR101709904B1/ko active IP Right Grant
- 2010-05-17 CN CN201080022208.3A patent/CN102438587B/zh active Active
- 2010-05-17 SG SG2011085297A patent/SG176159A1/en unknown
- 2010-05-17 PT PT107258808T patent/PT2432454T/pt unknown
- 2010-05-17 DK DK17158360.2T patent/DK3192500T3/da active
- 2010-05-19 AR ARP100101735A patent/AR078413A1/es not_active Application Discontinuation
- 2010-07-14 US US12/836,130 patent/US7863336B2/en active Active
- 2010-12-07 US US12/961,534 patent/US9101663B2/en active Active
-
2011
- 2011-11-15 IL IL216383A patent/IL216383A/en active IP Right Grant
- 2011-11-17 CL CL2011002895A patent/CL2011002895A1/es unknown
- 2011-12-08 ZA ZA2011/09037A patent/ZA201109037B/en unknown
-
2014
- 2014-05-13 US US14/276,235 patent/US9040590B2/en active Active
- 2014-05-13 US US14/276,211 patent/US9040589B2/en active Active
- 2014-10-30 JP JP2014221786A patent/JP5921002B2/ja active Active
-
2015
- 2015-07-01 US US14/789,214 patent/US9993451B2/en active Active
-
2016
- 2016-04-08 JP JP2016078121A patent/JP6157678B2/ja active Active
-
2017
- 2017-05-30 HR HRP20170805TT patent/HRP20170805T1/hr unknown
- 2017-05-31 CY CY20171100573T patent/CY1119495T1/el unknown
-
2018
- 2018-05-30 US US15/992,979 patent/US20190125708A1/en not_active Abandoned
-
2019
- 2019-01-16 RU RU2019101159A patent/RU2019101159A/ru unknown
- 2019-03-28 AR ARP190100805A patent/AR117412A2/es unknown
- 2019-12-23 AR ARP190103847A patent/AR117502A2/es unknown
-
2020
- 2020-04-30 US US16/863,459 patent/US20210077442A1/en not_active Abandoned
- 2020-12-21 HR HRP20202038TT patent/HRP20202038T1/hr unknown
-
2022
- 2022-11-11 US US17/985,556 patent/US20230321019A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201109037B (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
IL263954A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them | |
HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
HK1156306A1 (en) | Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4- | |
EP2470019A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS | |
HK1167999A1 (en) | Lysosomotropic inhibitors of acid ceramidase | |
PL2642993T3 (pl) | Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny | |
HU0900072D0 (en) | Transdermal pharmaceutical compositions | |
EP2616053A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN | |
ZA201203012B (en) | Solid pharmaceutical compositions containing an intergrase inhibitor | |
ZA201107122B (en) | Stable pharmaceutical compositions of diclofenac | |
EP2152232A4 (en) | METHOD AND COMPOSITIONS FOR OXYBUTYNINE ADMINISTRATION | |
EP2424533A4 (en) | SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS | |
ZA201300009B (en) | Oral formulation of kinase inhibitors | |
PT2411376E (pt) | Inibidores de nf-kb | |
EP2543373A4 (en) | PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND | |
IL215486A0 (en) | Compositions of cholinesterase inhibitors | |
EP2484367A4 (en) | MEANS OF PREVENTING UNWANTED SIDE EFFECTS OF A CARCINUTATIVE MEDIUM | |
IL226239B (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them | |
GB0803895D0 (en) | Inhibitors of glyoxalase |